GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Cyclically Adjusted PS Ratio

Hanall Biopharma Co (XKRX:009420) Cyclically Adjusted PS Ratio : 11.13 (As of Jun. 01, 2025)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Cyclically Adjusted PS Ratio?

As of today (2025-06-01), Hanall Biopharma Co's current share price is ₩25900.00. Hanall Biopharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩2,328.06. Hanall Biopharma Co's Cyclically Adjusted PS Ratio for today is 11.13.

The historical rank and industry rank for Hanall Biopharma Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

XKRX:009420' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.91   Med: 10.66   Max: 20.74
Current: 11.13

During the past years, Hanall Biopharma Co's highest Cyclically Adjusted PS Ratio was 20.74. The lowest was 3.91. And the median was 10.66.

XKRX:009420's Cyclically Adjusted PS Ratio is ranked worse than
92.68% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs XKRX:009420: 11.13

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hanall Biopharma Co's adjusted revenue per share data for the three months ended in Mar. 2025 was ₩696.822. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₩2,328.06 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Hanall Biopharma Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Hanall Biopharma Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Cyclically Adjusted PS Ratio Chart

Hanall Biopharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.46 10.49 8.40 19.88 16.85

Hanall Biopharma Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.57 13.72 17.01 16.85 11.79

Competitive Comparison of Hanall Biopharma Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Hanall Biopharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanall Biopharma Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hanall Biopharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hanall Biopharma Co's Cyclically Adjusted PS Ratio falls into.


;
;

Hanall Biopharma Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Hanall Biopharma Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=25900.00/2328.06
=11.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanall Biopharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Hanall Biopharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=696.822/122.5900*122.5900
=696.822

Current CPI (Mar. 2025) = 122.5900.

Hanall Biopharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 570.616 100.051 699.164
201509 391.944 100.111 479.952
201512 404.066 100.220 494.255
201603 419.347 100.561 511.210
201606 399.451 100.791 485.845
201609 387.702 101.461 468.439
201612 423.648 101.561 511.366
201703 368.826 102.851 439.612
201706 414.781 102.611 495.540
201709 482.225 103.491 571.221
201712 403.355 102.991 480.114
201803 431.176 104.101 507.757
201806 442.199 104.130 520.590
201809 470.093 105.651 545.465
201812 436.661 104.351 512.984
201903 475.354 104.491 557.691
201906 583.198 104.881 681.671
201909 548.929 105.200 639.667
201912 512.618 105.121 597.803
202003 433.166 105.354 504.031
202006 440.772 105.112 514.064
202009 434.671 106.198 501.766
202012 422.734 105.765 489.980
202103 540.547 107.357 617.245
202106 459.945 107.579 524.125
202109 494.693 108.759 557.603
202112 491.235 109.676 549.074
202203 579.574 111.848 635.237
202206 679.653 114.072 730.402
202209 565.093 114.715 603.884
202212 676.183 115.179 719.690
202303 574.457 116.507 604.448
202306 816.295 117.182 853.967
202309 620.481 118.964 639.395
202312 613.623 118.837 633.001
202403 632.702 120.123 645.695
202406 627.379 120.007 640.881
202409 664.005 120.861 673.503
202412 736.641 121.135 745.488
202503 696.822 122.590 696.822

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hanall Biopharma Co  (XKRX:009420) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Hanall Biopharma Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanall Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co Headlines

No Headlines